Treatment Response to Xiaflex for Men With Peyronie's Disease
Treatment Response to Xiaflex Based on Ultrasound Characterization of Plaque for Men With Peyronie's Disease
Sponsor: Endo Pharmaceuticals
This observational or N/A phase trial investigates Peyronie Disease and is currently completed. Endo Pharmaceuticals leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Oct 2021 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting
Phase: PHASE4 → None
▶ Show 4 earlier versions
-
Sep 2019 — Sep 2020 [monthly]
Recruiting PHASE4
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE4
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE4
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE4
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Endo Pharmaceuticals
- University of Miami
For direct contact, visit the study record on ClinicalTrials.gov .